IP Library Granted Patent US 12,491,304
Granted Patent B2
US 12,491,304 · App. 18/797,358 · Granted Dec 9, 2025

Treating circulating cell clusters

Inventors: Mark A. Rosenberg (Boca Raton, FL); James W. Hill (Las Vegas, NV)
Assignee: OncoClear, Inc.
A61M1/362264A61M1/3401A61M1/3406A61M1/36224A61M2202/0021A61M2202/0028A61M2202/0042A61M2202/005A61M2202/0427A61M2202/0443A61M2202/097A61M2205/0216A61M2205/0233A61M2205/0255A61M2205/10A61M2205/126A61M2205/3327A61M2205/3334A61M2205/7527A61M2205/7545
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,491,304
App. No.
18/797,358
Granted
Dec 9, 2025
Kind
B2
Abstract

Circulating cell clusters found in subjects with cancer, autoimmune conditions, infections, or other diseases, can be trapped or disrupted by filtering them with an intra- or extracorporeal device and, in some cases, exposing them to a substance, such as enzyme, that reduces intercellular adhesion.

Claims (16)

1 . A method of removing circulating cancer-associated cell clusters from a subject, the method comprising:

connecting a portion of the subject's blood stream to a system thereby allowing the subject's blood to flow into the system:

wherein the system comprises a filtering module comprising: (a) an input port, (b) an output port, and (c) a membrane having pores configured to allow at least a portion of a subject's blood to pass through the pores from a first side to a second side of the membrane;

wherein the pores in the membrane have a minimum size not less than about 20 microns, configured to allow individual cancer-associated cells to pass through the pores from the first side to the second side of the membrane;

wherein the input port is configured to allow the subject's blood to flow into a first chamber to contact the membrane;

wherein the filtering module is configured to retain circulating cancer-associated cell clusters on the first side of the membrane, each cluster comprising three or more cells; and

wherein the filtering module is configured to allow individual circulating cancer cells in the subject's blood to pass through the pores to the second side of the membrane and into a second chamber and return to the subject's blood circulation via the output port; and

returning blood from the second chamber to the subject's blood circulation via the output port.

2 . The method of claim 1 , wherein the subject is a mammal.

3 . The method of claim 1 , wherein the subject is a human.

4 . The method of claim 1 , further comprising performing the method once or twice a week.

5 . A method of removing circulating cancer-associated cell clusters from a subject, comprising:

introducing a portion of a subject's blood circulation into a filter comprising a membrane having pores that permit at least some of the subject's blood to pass through the pores from a first side to a second side of the membrane;

wherein the pores have a minimum size not less than about 20 microns and are sized and configured to permit individual cancer-associated cells to pass freely through the pores from the first side to the second side of the membrane;

wherein the pores are further sized and configured to prevent circulating cell clusters from passing through the pores, each of the circulating cell clusters comprising three or more cells; and

returning blood from the second side of the membrane to the subject's blood circulation.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2024
From: ROSENBERG, MARK A.; HILL, JAMES W.
To: ONCOCLEAR, INC.
Reel/Frame 069502/0943 →
Continuity (2)
Provisional Application 63531255 · Aug 7, 2023
Related Publication 20250050005A1 · Feb 13, 2025
References Cited (8)
US 9545471B2 · van Rijn et al. · 2017 [cited by applicant]
US 11607480B2 · Keaney et al. · 2023 [cited by applicant]
US 11724015B2 · Surkov · 2023 [cited by applicant]
US 20150041398A1 · van Rijn · 2015 [cited by examiner]
US 20200264166A1 · Paterlini-Brechot · 2020 [cited by examiner]
Schuster et al, “Better together: circulating tumor cell clustering in metastatic cancer,” Trends in Cancer, Nov. 2021, vol. 7, No. 11. (Year: 2021). [cited by examiner]
PCT International Search Report and Written Opinion, PCT Application No. PCT/US2024/41336, Oct. 18, 2024, 14 pages. [cited by applicant]
Tamminga, M. et al., “Detection of Circulating Tumor Cells in the Diagnostic Leukapheresis Product of Non-Small-Cell Lung Cancer Patients Comparing CellSearch® and ISET,” Cancers, vol. 12, Apr. 7, 2020, pp. 1-15. [cited by applicant]